Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib plus Trametinib in BRAFV600E-mutated Differentiated Thyroid Cancer
NCT04940052Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2021
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of dabrafenib + trametinib, trametinib in differentiated thyroid cancer (DTC), sponsored by Novartis. Started Nov 2021; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT04940052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04940052.